Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7911
Peer-review started: September 24, 2023
First decision: October 9, 2023
Revised: October 23, 2023
Accepted: November 2, 2023
Article in press: November 2, 2023
Published online: November 16, 2023
Processing time: 52 Days and 15.6 Hours
SMARCB1/INI-1 deficient sinonasal carcinoma (SDSC) is a rare subset of sinonasal undifferentiated carcinoma with a poor prognosis. Here, we present two case reports of SDSC patients. We also review the literature on this tumor. This is the first published report of SDSC treatment with immunotherapy.
Here we present two patient cases of SDSC in which initial consultation and diagnosis were complicated but SDSC was ultimately diagnosed. One patient received a traditional treatment of surgery and adjuvant chemoradiotherapy, while the other patient received additional immunotherapy; the prognoses of these two patients differed. We review previous diagnostic literature reports and SDSC treatments and provide a unique perspective on this rare type of tumor.
SDSC is a rare, diagnostically challenging carcinoma with a consistently poor prognosis, early distant metastases, and frequent recurrence. Timely diagnosis and intervention are critical for treatment, for which the standard of care is surgery followed by adjuvant chemoradiotherapy, though immunotherapy may be an effective new treatment for SDSC.
Core Tip: SMARCB1/INI-1 deficient sinonasal carcinoma (SDSC) is a rare carcinoma with a poor prognosis and no standard treatment guidelines. Currently, the most effective treatment option is surgery followed by adjuvant chemoradiotherapy. Here, we present two SDSC patients with complicated consultation experiences. The patients differed in treatments and prognoses, and there was no indications of local recurrence or distant metastases in patient with immunotherapy. We also review the literature on SDSC treatment. This first report on immunotherapy in SDSC provides a unique perspective on treatments for this rare tumor.